Stockscreener 앱 받기
11.49
0.52%
-0.06
시장 영업 전:
11.53
0.04
+0.35%
전일 마감가:
$11.55
열려 있는:
$11.53
하루 거래량:
3.42M
Relative Volume:
0.61
시가총액:
$7.84B
수익:
$125.68M
순이익/손실:
$4.81B
주가수익비율:
2.0336
EPS:
5.65
순현금흐름:
$-781.21M
1주 성능:
+1.59%
1개월 성능:
+5.80%
6개월 성능:
+5.51%
1년 성능:
+5.90%
1일 변동 폭
$11.40
$11.58
1주일 범위
$11.22
$11.72
52주 변동 폭
$8.73
$13.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
명칭
Roivant Sciences Ltd
전화
441-295-5950
주소
7TH FLOOR, 50 BROADWAY, LONDON
ROIV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
11.49 | 7.95B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-01-05 | 개시 | Piper Sandler | Overweight |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-17 | 개시 | Guggenheim | Buy |
| 2023-06-08 | 개시 | BofA Securities | Neutral |
| 2022-10-27 | 개시 | JP Morgan | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 개시 | Goldman | Buy |
| 2021-11-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-28 | 개시 | Citigroup | Buy |
| 2021-10-26 | 개시 | Cowen | Outperform |
| 2021-10-26 | 개시 | Jefferies | Buy |
| 2021-10-26 | 개시 | Truist | Buy |
모두보기
Roivant Sciences Ltd 주식(ROIV)의 최신 뉴스
Roivant Sciences Earnings Expectations: A Closer Look at the Company's Performance and Analyst Sentiments - AInvest
Barrick Gold, Roivant Sciences, Owens & Minor to report earnings Monday - Investing.com Australia
A Glimpse of Roivant Sciences's Earnings Potential - 富途牛牛
What To Expect From Roivant Sciences Ltd (ROIV) Q1 2026 Earnings - Yahoo Finance
Roivant Sciences Ltd. shares fall 1.12% intraday as Sumitomo Pharma submits application for Parkinson's disease treatment. - AInvest
Sector ETF Data Correlates with Strength in Roivant Sciences Ltd.Exit Ready Momentum Stock Watchlist Expanded - beatles.ru
What analysts say about Roivant Sciences Ltd. stockDynamic investment opportunities - Jammu Links News
What is the risk reward ratio of investing in Roivant Sciences Ltd. stockAchieve rapid wealth accumulation with smart picks - Jammu Links News
Why is Roivant Sciences Ltd. stock attracting strong analyst attentionMaximize returns with effective portfolio management - Jammu Links News
How does Roivant Sciences Ltd. generate profit in a changing economyTrack emerging stocks with high growth potential - Jammu Links News
What is the dividend policy of Roivant Sciences Ltd. stockCapitalize on momentum stocks early - Jammu Links News
Should I hold or sell Roivant Sciences Ltd. stock in 2025Capitalize on fast-moving stock trends - Jammu Links News
How volatile is Roivant Sciences Ltd. stock compared to the marketExceptional risk-adjusted gains - Jammu Links News
What institutional investors are buying Roivant Sciences Ltd. stockAchieve exceptional returns with expert guidance - Jammu Links News
What are analysts’ price targets for Roivant Sciences Ltd. in the next 12 monthsInvest confidently with professional market insights - Jammu Links News
Is Roivant Sciences Ltd. a growth stock or a value stockDiscover undervalued stocks before they soar - Jammu Links News
What makes Roivant Sciences Ltd. stock price move sharplyTop Performing Stock Strategy Prediction - beatles.ru
Is it the right time to buy Roivant Sciences Ltd. stockChart Pattern Planner For Fast Growth - Jammu Links News
Is Roivant Sciences Ltd. showing signs of accumulationEntry Points For Growing Stocks Identified by Models - metal.it
Roivant Sciences Ltd. Building a Base Near SupportShort Term Trading Opportunity Watch Sees Shift - beatles.ru
Recovery Signals Appearing in Roivant Sciences Ltd. ChartsConsistent Income Focused Trade List Analyzed - metal.it
Is Roivant Sciences Ltd. Starting a New UptrendReal-Time Trade Insights Spark Market Reactions - metal.it
What caused the surprising earnings drop in Q2 2025 for ROIV? - AInvest
Published on: 2025-07-29 10:36:14 - metal.it
Roivant Sciences Ltd. Consolidation Zone May Signal AccumulationChart Driven High Reward Trading Setup Presented - metal.it
Roivant to Reveal Q1 2025 Financial Performance and Strategic Updates: Key Details for August 11 Earnings Call - Stock Titan
Published on: 2025-07-28 06:27:01 - jammulinksnews.com
Is Roivant Sciences Ltd. a Top Dividend Stock to Watch in 2025High Return Conservative Stocks - metal.it
Published on: 2025-07-27 16:10:26 - Jammu Links News
Is Roivant Sciences Ltd. a good long term investmentUnbelievable profit margins - Autocar Professional
Roivant Sciences (ROIV) Anticipated to Benefit from Brepocitinib Developments | ROIV Stock News - GuruFocus
Vivek Ramaswamy to welcome third child soon: Meet his wife and his two elder sons - Times of India
Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with ‘Buy’ Rating - MSN
Roivant Sciences Ltd. Stock Analysis and ForecastFree Stock Market Beginners Guide - Autocar Professional
Roivant Sciences’ president Venker sells $1.15 million in shares By Investing.com - Investing.com South Africa
Roivant Sciences’ president Venker sells $1.15 million in shares - Investing.com Australia
Roivant Sciences President Eric Venker Sells 100k Shares at $11.52, Buys 100k at $3.85. - AInvest
10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen - Insider Monkey
What drives Roivant Sciences Ltd. stock priceExceptional risk-adjusted gains - jammulinksnews.com
Roivant Sciences Ltd (ROIV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):